US$ 25.81
semaglutide gastrointestinal obstruction lawsuit in kentucky lawyer GLP-1 Attorneys kentucky semaglutide gastric intestinal obstruction
Description
They are not medications, nor are they intended to diagnose, treat, prevent, or cure any disease or medical condition

J Endocr Soc 7:bvad074

This article is intended for informational purposes only and does not constitute medical advice

spin-out built around Hengrui-licensed incretin assets - IPO'd in 2025 with HRS-4729 as part of a portfolio anchored on HRS9531 (a dual GLP-1/GIP agonist that read out ~17.7% weight loss in Phase 3 in China in February 2026)

Visible signs of degradationcloudiness, discoloration, or crystallizationwarrant immediate discarding and replacement with a fresh vial
